Precision research, phytochemical screening, and end-to-end preclinical-to-commercial OEM solutions developed to de-risk life science investments.
The global pharmaceutical and nutraceutical sectors are navigating a transformative structural shift. For decades, global enterprises relied on transactional Contract Manufacturing Organizations (CMOs) primarily focused on cost arbitrage and mechanical toll processing. However, the surging clinical demand for botanical drug candidates, complex phyto-formulations, and rigorously standardized bio-actives has exposed the limitations of traditional outsourcing models. Modern sponsors require a Contract Development Organization (CDO / CDMO) that pairs deep scientific inquiry with scalable industrial execution.
Botanical active pharmaceutical ingredients (APIs) present intrinsic complexities unlike synthetic small molecules. Natural raw materials fluctuate drastically in secondary metabolite concentrations due to geographic origins, harvesting seasons, microclimates, and post-harvest drying protocols. A true contract development partner must operate at the intersection of natural product chemistry, pharmacokinetics, and process engineering—transforming empirical herbal medicine into reproducible, regulatory-compliant, evidence-based global therapeutics.
Wild variations in raw botanical active densities destabilize therapeutic efficacy. Strategic CDOs implement fingerprinting standards (HPLC, HPTLC) to normalize active yields across supply cycles.
Agencies including US FDA, EMA, and NMPA demand stringent trace-level safety profiles: LD50, genetic toxicology, heavy metal quantification, and residual solvent clearance.
Over 65% of botanical formulations fail during thermal or solvent scale-up. Integrated CDMOs bridge bench discovery with directly managed pilot plants to secure linear yield retention.
Procurement executives and Chief Scientific Officers (CSOs) evaluating OEM Contract Development Organization suppliers look beyond unit pricing. In today’s regulated bioscience ecosystem, user intent pivots around verifiable analytical transparency, Quality by Design (QbD) frameworks, and intellectual property custody.
ICH Q2(R1) compliant analytical protocols, validated chromatography curves, and quantitative multi-component identification.
Cellular mechanism testing, pharmacokinetic (PK) distribution assays, sub-chronic toxicity data, and proof-of-concept animal validation.
Pilot plant extraction, ultra-concentration, and drying parameter transfer without thermal degradation of delicate bioactives.
Robust legal confidentiality, single-client formulation custody, and complete data ownership transfer under OEM contract clauses.
Established in Changsha, Hunan, China, MedGence (Yineng Pharma) stands as a benchmark full-lifecycle natural medicine Contract Development and Manufacturing Organization. Over 14+ years of focused operational history, our scientific infrastructure has bridged ancient pharmacopoeias with contemporary Western medicine through rigorous biophysical screening and certified GMP manufacturing.
Our integrated technical continuum guarantees seamless progression through every drug discovery and botanical product life stage. From crude herbal raw material screening to commercial finished dosage distribution, our multidisciplinary team coordinates analytical validation, safety profiling, clinical trials, and multi-ton OEM batch supply.
Quantitative identification of active compounds across plant varieties, regional topographies, and seasonal harvesting cycles.
Creation of proprietary HPLC, HPTLC, and GC fingerprint profiles to establish reproducible chemical markers for identity and batch conformity.
Multi-stage extraction, counter-current chromatography, resin adsorption, and low-temperature vacuum crystallization parameters optimization.
Cell-line efficacy models, LD50 acute screening, 90-day subchronic oral toxicity, and Ames/micronucleus genotoxicity safety panels.
Protocol formulation, IRB approval, cohort human trials for dietary claims, and full Phase I–IV clinical designs for regulatory drug dossiers.
Direct cGMP production of concentrated extracts, vacuum-dried crystals, oral liquids, hard-shell capsules, tablets, and functional micro-granules.
Cross-border procurement demands rigorous compliance with the world's primary public health bodies. MedGence standardizes and documents every research and manufacturing cycle to seamlessly support regional drug master files (DMF), novel food submissions, and OTC monographs across major jurisdictions:
Botanical Drug Guidance protocols, 21 CFR 111 cGMP dietary supplement compliance, and 21 CFR 210/211 active pharmaceutical ingredient documentation.
Adherence to the Committee on Herbal Medicinal Products (HMPC), Well-Established Use dossiers, Traditional Herbal Medicinal Products Directive (THMPD), and Ph. Eur. monographs.
China National Medical Products Administration registered hospital preparation protocols, Class 1 and Class 2 innovative natural medicine dossiers, and ASEAN harmonization guidelines.
Over 14 years, our contract research, assay designs, and CDMO operations have supported the premier pharmaceutical institutions across Asia.
Direct technical answers addressing tech transfer, analytical rigor, scale-up hurdles, regulatory filings, and intellectual property protection.
Engage our scientific team across individual modular milestones or commission full-scope turnkey CDMO pipelines.
Consult directly with our Changsha scientific leadership team. Submit your target indication, chemical compound marker, or desired dosage format for rapid feasibility assessment and scoping.